Verve Therapeutics (NASDAQ:VERV) Receives “Neutral” Rating from HC Wainwright
HC Wainwright restated their neutral rating on shares of Verve Therapeutics (NASDAQ:VERV – Free Report) in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a $13.50 price target on the stock. Several other research firms have also recently issued reports on VERV. Canaccord Genuity Group cut shares of Verve Therapeutics […]
HC Wainwright restated their neutral rating on shares of Verve Therapeutics (NASDAQ:VERV – Free Report) in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a $13.50 price target on the stock. Several other research firms have also recently issued reports on VERV. Canaccord Genuity Group cut shares of Verve Therapeutics […]
